Further evidence supports Pomalidomide’s efficacy in reversing immune dysfunction associated with MM, such as impaired T-cell distribution and reduced peripheral blood CD4 + and CD8 + T-cells, partly due to TGF-β secretion [16, 47]. The gene discussed is CD4; the disease is Miyoshi myopathy.